Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First report: PLATFORM study for precision treatment of rare tumors in China.

Cancer letters - 10 Aug 2024

Zhou Jiawei, Ma Peiwen, Jiang Yale, Xing Shujun, Wang Shuhang, Li Ning

Abstract excerpt

The purpose of this study was to present the preliminary results of the PLATFORM Study, which aimed to evaluate the effectiveness of precision treatment for rare tumors in China. This study involved a phase II, open-label, non-randomized, multi-arm, single-center clinical trial. Patients with advanced rare solid tumors, who had not responded to standard treatment, were enrolled. The primary objective was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to China
Share to Immune Checkpoint Inhibitors
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Neoplasms

Share to Precision Medicine

Share to Progression-Free Survival

Share to Rare Diseases

Source

Identifiers

PMID: 38876388
DOI: 10.1016/j.canlet.2024.217021

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First report: PLATFORM study for precision treatment of rare tumors in China.PMID 38876388Read ↗

Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours.Semantic proximity Read ↗

Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future PerspectivesSemantic proximity Read ↗

The Future of Precision Oncology.Semantic proximity Read ↗

Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.Semantic proximity Read ↗

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer TherapeuticsSemantic proximity Read ↗

Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases.Semantic proximity Read ↗

Pragmatic Nationwide Master Observational Trial Based on Genomic Alterations in Advanced Solid Tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II Study Protocol KCSG AL-22-09Semantic proximity Read ↗

Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapySemantic proximity Read ↗

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer TherapeuticSemantic proximity Read ↗

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer TherapeuticSemantic proximity Read ↗

Precision Oncology, Signaling Pathways Reprogramming and Targeted Therapy: A Holistic Approach to Molecular Cancer TherapeuticsSemantic proximity Read ↗

The Precision Medicine: Advancement and Transformation in Cancer TreatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.